<DOC>
	<DOCNO>NCT02635997</DOCNO>
	<brief_summary>Ibandronate third-generation biphosphonate recognize antiresorptive efficacy several international , randomize , double-blind , control trial . These study include patient central america , best knowledge . Therefore , open-label , uncontrolled study , set assess clinical effect 6-m treatment course Ibandronate plus vitamine D Calcium bone mineral density health-related quality life .</brief_summary>
	<brief_title>Antiresorptive Effects 6-m Treatment Course With Ibandronate Plus Supplementation Vitamine D Calcium Central America</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women diagnosis osteoporosis atRisk Have medical indication receive Ibandronate+Vitamine D+Calcium Osteoporosis due secondary cause</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>ibandronate</keyword>
	<keyword>vitamine D</keyword>
	<keyword>calcium</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>health-related quality life</keyword>
</DOC>